ʻO ka Atherosclerosis ke kumu nui o ka maʻi cardiovascular, e noho mau ana i ke alakaʻi honua i ka make. ʻO ka insulin-like growth factor I (IGF1) ua hōʻike ʻia e hōʻemi i nā hanana cardiovascular. ʻO ka hoʻokele ʻana o IGF1 i hoʻemi i ka atherosclerosis a me nā macrophages plaque i hōʻemi ʻia i ApoE-deficient (Apoe- /-) hānai nā ʻiole i ka meaʻai momona nui. ʻO kā mākou mau hopena in vitro mua e hōʻike ana he hana nui nā macrophages i ka hoʻopili ʻana i nā hopena o IGF1 i nā pā atherosclerotic, akā ʻaʻole maopopo ke ʻano pololei. pale i ka atherosclerosis.
Ma hope o ka hoʻoulu ʻana i ka moʻolelo macrophage-specific IGF1-overexpressing transgenic mice i loko o ka Apoe-/- hope (MF-IGF1 mice), ua loiloi mākou i ka kaumaha plaque atherosclerotic, kūpaʻa, a me ka recruitment monocyte. ʻAi momona no nā mahina ʻekolu. Ua loiloi pū mākou i ka cholesterol efflux a me ka hoʻokumu ʻana o nā cell foam ma vivo a in vitro.
Macrophage IGF1 overexpression downregulated plaque kaumaha e 30%, hoemi plaque macrophages e 47%, a paipai 'ana i nā hiʻona e stabilize i ka plaque phenotype.Monocyte recruitment ua hoemi ia e 70% ma MF-IGF1 mice a hooponopono me ka 27% hoemi i ka circulating pae o CXC. chemokine ligand 12 (CXCL12) .CXCL12 pae protein i hoemiia i loko o plaques a me peritoneal macrophages i MF-IGF1 mice.In vitro, IGF1 ālai loa oxidized haʻahaʻa-density lipoprotein (oxLDL)-pili i ka CXCL12 mRNA transcription (98% ho'ēmi, P <0.01), a me IGF1 ho'ēmi i ka CXCL12 protein (56% ho'ēmi, P<0.001).
Hoʻemi ʻo CXCL12 i ka hōʻike ʻana o ka ATP-binding cassette transporter A1 (ABCA1), kahi mea lawe cholesterol kī e hoʻopili ana i ka cholesterol efflux mai macrophages. Ua loaʻa iā mākou he piʻi 2-fold i nā pae protein ABCA1 i nā macrophages peritoneal i hoʻokaʻawale ʻia mai nā mice MF-IGF1. Ua ana mākou i nā loli. i loko o ka cholesterol efflux ma ka hoʻoukaʻana i nā macrophages peritoneal me ka oxLDL a loaʻa he 42% ka piʻiʻana o ka efflux ma nāʻiole MF-IGF1. Ua loaʻa pū mākou he 27% ka piʻiʻana o ka cholesterol efflux ma nā pūnaewele THP-1 i mālamaʻia me IGF1 (100 ng / mL) me ka apolipoprotein AI e like me ka mea i loaʻa i ka cholesterol.
Hōʻike kā mākou mau hopena i ka macrophage IGF1 e hōʻemi i ka atherosclerosis a hoʻemi i ka CXCL12, kahi chemokine i komo hou i ka holomua atherosclerosis. Hiki i ka IGF1 ke hōʻemi i ka CXCL12 ma o ka hoʻemi ʻana i ka monocyte recruitment a me ka hoʻonui ʻana i ka ABCA1, a laila e hoʻohana ana i kāna hopena atheroprotective, a laila e hoʻonui ai i ka hiki o ka cholesterol efflux.
ʻIke ʻia ka hoʻololi ʻana i ka gene TTR (rs76992529; Val122Ile) i nā poʻe o nā kūpuna o ʻApelika (ka nui o ka heluna kanaka: 3-4%) ka hopena o ka hoʻololi hewa ʻana o ka paʻakikī transthyretin tetrameric, i loaʻa i ka amyloidosis transthyretin hereditary.Hōʻiliʻili ka Degeneration (hATTR) ma ke ʻano he extracellular amyloid fibrils. ʻO ka manaʻo ʻana i ka hopena o kēia ʻano amyloidogenic TTR i ka pilikia o ka puʻuwai (HF) a me nā kumu make āpau i loko o kahi pūʻulu nui o ʻAmelika ʻAmelika hiki ke hāʻawi i ka ʻike i ke ʻano koʻikoʻi o kēia ʻano. .Ua loiloi mākou i nā poʻe ʻeleʻele i ka haʻawina Geographic and Racially Different Causes of Stroke (REGARDS) e nānā i ka hui ʻana o ka TTR Val122Ile mutation me HF a me nā kumu make āpau.
Ua loiloi mākou i nā poʻe ʻAmelika ʻeleʻele i hōʻike iā lākou iho i ka REGARDS study me ka ʻole o ka HF ma ke kumu. nā kumu, a me nā moʻomeheu ʻApelika e loiloi i ka pilikia o ka HF a me nā kumu āpau i ka make i nā poʻe me ka TTR Val122Ile genetic variant i hoʻohālikelike ʻia me ka poʻe me ka ʻole o ka ʻokoʻa.
Ma waena o 7,514 ʻeleʻele i komo (median makahiki: 64 makahiki; 61% wahine), ʻo ka heluna heluna o ka TTR Val122Ile ʻano like ʻole he 3.1% (232 mea lawe; 7,282 mea lawe ʻole). (95% CI: 11.5-21.9) ma waena o nā mea lawe ʻokoʻa a me 7.2 (95% CI: 6.6-7.9) ma waena o nā mea ʻokoʻa ʻole. : 1.72–3.53]; P<0.0001) ʻO ka nui o nā kumu make a pau (no 1000 kanaka-makahiki) he 41.5 (95% CI: 34.6-49.7) ma waena o nā mea lawe ʻokoʻa a me 33.9 (95% CI: 32.7-35.2) ma waena o nā mea lawe ʻole like ʻole. Ua ʻoi aku ka kiʻekiʻe o nā mea lawe ʻokoʻa ʻo Val122Ile i ka make ʻana o nā kumu āpau i hoʻohālikelike ʻia me nā mea lawe ʻole (HR: 1.44 [95% CI: 1.18-1.76]; P=0.0004). e launa pū me ka HF a me nā hopena make.
I loko o kahi hui nui o nā ʻAmelika ʻeleʻele, hōʻike mākou e pili ana ka amyloid Val122Ile mutation i ka TTR gene me kahi 2.5-paʻi kiʻekiʻe o ka HF a ma kahi o 40% kiʻekiʻe o ka make ʻana o nā kumu āpau. ʻO ka loaʻa ʻana o ka TTR Val122Ile mutation i ʻike pinepine ʻia i nā poʻe o nā kūpuna o ʻApelika hiki ke noʻonoʻo ʻia he hiki ke hana a hiki koke i ka lāʻau lapaʻau.
ʻO ka hoʻoulu ʻana o ka guanylate cyclase/natriuretic peptide receptor A (GC-A/NPRA) e nā hormones cardiac atrial a me ka lolo natriuretic peptides (ANP a me BNP) e hoʻopuka i ka lua o ka ʻelele cGMP. , diuretic, vasodilatory, antimitotic responses and cardiac antihypertrophic effects.ʻO ka'ōlelo o ka Npr1 gene (encoding GC-A / NPRA) ua hoʻoponoponoʻia e kekahi mau mea hoʻoulu waho a me loko, akā,ʻaʻole iʻikeʻia nāʻano hormonal a me epigenetic e hoʻoponopono i ka hoʻoponopono Npr1. ʻAʻoleʻikeʻia ka pahuhopu. ʻO kēia haʻawina ʻo ia ka nānā ʻana i ke kuleana o ka vitamina D (vitD) i ka hoʻoponopono ʻana i ka transcription gene Npr1 a me ka hōʻike ʻana ma o ka hoʻoponopono ʻana i nā mea epigenetic.
ʻO kā mākou noiʻi bioinformatic o ka mea hoʻolaha murine Npr1 i hōʻike i ka loaʻa ʻana o ʻehā mau mea pane pane vitD (VDREs) ma ka -583 a i ka -495 ʻāpana o ka wahi hoʻomaka transcription, me kahi ʻano ʻae like VDRE-like. , ua ho'ololi 'ia nā mea i kūkulu 'ia i loko o ka mo'omeheu rat thoracic aortic smooth muscle cell (RTASMCs) a me nā pūnaewele mesangial mouse (MMCs) a ana 'ia no nā pahu ho'ā'o luciferase lua.Hana unuhi.
Ua hōʻike ʻo Luciferase assay i ka hoʻomaʻamaʻa ʻana me ka vitamina D3 (1α,25-dihydroxy; VD3) i hoʻonui i ka hana hoʻolaha Npr1 ma mua o 6-fold ma ke ʻano pili i ka dose. ka hoʻopaʻa ʻana, 3.5-fold ma RTASMCs a me 4.7-fold ma RTASMCs, a ua ʻike ʻia ka hopena kiʻekiʻe loa ma 100 nM.VD3 e hoʻonui i ka pae protein o ka vitD receptor (VDR) ma ke ʻano o ka hopena. deacetylase (HDAC) hana ua 50% inhibited e like me ana e ka HDAC hana / inhibition ELISA kit. Eia kekahi, lapaau me VD3 hoemi papa I HDAC enzymes, HDAC1 a me HDAC3 protein pae, a me ka dosis-dependently hoʻonui histones, H3 ma lysine koena 9 a 14 (H3-K9/14 ac) a me ka lysine H4 ma ke koena waikawa 12 (H4-K14ac).
Hōʻike nā hopena i ka VD3 epigenetically hoʻoponopono i ka Npr1 gene expression ma ka hoʻoponopono ʻana i nā hoʻololi histone. ʻO ka ʻike ʻana i nā pahuhopu epigenetic o ka vitamin D hōʻailona ma ke ʻano he regulators o ka Npr1 gene transcription a me ka hōʻike protein e loaʻa i nā hopena koʻikoʻi no ka hypertension a me ka hoʻoponopono cardiovascular.
ua hōʻike i ka entanglement a me ka superconductivity i hoʻomaikaʻi i ka intracellular conduction i nā pālua o nā cardiomyocytes kaʻawale, hoʻomaikaʻi i ka hui ʻana a me ka hana ventricular hema.
Ua hana ʻia nā hoʻokolohua me ka hoʻohana ʻana i ka naʻauao hana i loko o nā cell me ka hoʻohana ʻana i nā manaʻo quantum o ka entanglement a me ka superconductivity;Ua ana ʻia ka conductance uila intracellular ma waena o ka ʻāpana junctional (GI) i hoʻoulu ʻia e enalapril (E.) a me angiotensin II (Ang II).Inject ma 1 ug / ml (25 ug / ml) ma luna o 4 minuke. Loaʻa ka pāpū ma ka valve ma 106% kahe mai kaʻeke. ʻaʻohe pāpū.
Manaʻo mākou ua loaʻa kahi pāpū ma hope o ka hoʻohaʻahaʻa ʻana i ka entanglement, akā ʻaʻole me Ang II. Ma ke kūlana superconducting, ʻoi aku ka maikaʻi o E. coli i ka hoʻomaikaʻi ʻana i ka hui ʻana o nā myocytes hemahema, hoʻomaikaʻi i ka hana ventricular hema.
ʻO ka maʻi Coronavirus (COVID-19) mai ka maʻi asymptomatic a i ka maʻi koʻikoʻi me ka hāʻule ʻole o ke kino. cholesterol (TC), a me ka maʻi maʻi COVID-19. Akā naʻe, ʻaʻole i kūlike nā hopena, a ʻaʻole ʻike ʻia ka nui o ka hui i kēia manawa.
Ua hana mākou i kahi loiloi ʻōnaehana a me ka meta-analysis o 1) ʻokoʻa i nā pae HDL, LDL, TC, a me triglyceride (TG) ma waena o nā maʻi COVID-19 a me nā mana olakino 2) me ka maʻi ʻole a me ka maʻi ʻole me ka maʻi COVID-19 3) COVID- Ua make a ola ka mea maʻi 19. Ua hoʻokomo mākou i nā ʻatikala mai PubMed a me Embase mai ka lā 1 o Kepakemapa 2021. Ua nānā mākou i ka ʻokoʻa ʻokoʻa o ka pooled mean (pMD) i nā pae lipid (mg/dL) o nā pūʻulu ma luna me ka hoʻohana ʻana i kahi hōʻike meta-hopena. a loiloi i ka hoʻolaha hoʻolaha ʻana me ka hoʻohana ʻana i kahi ʻāpana funnel.
No nā ʻatikala 441 i kiʻi ʻia, 29 mau ʻatikala (26 retrospective cohorts a me 3 prospective cohorts) i hoʻokō i nā koina hoʻokomo, me ka huina o 256,721 mau mea komo. -14.9) (Table 1 and Figure 1). ʻAʻole ʻokoʻa nā pae LDL a me TG ma waena o nā maʻi me ka COVID-19 a me ka ʻole. ) a me TC (pMD = -10.4) i hoʻohālikelike ʻia me nā maʻi maʻi COVID-19 koʻikoʻi ʻole. ʻO nā poʻe maʻi i make he mau pae haʻahaʻa o HDL (pMD = -2.5), LDL (pMD = -10.6) a me TC (pMD = -14.9). ʻAʻole ʻokoʻa nā pae TG mai ka nui o ka COVID-19 a i ʻole ka make.
Ua hōʻike kā mākou hōʻike ʻana i nā mea maʻi me COVID-19 he haʻahaʻa haʻahaʻa o ke koko lipid i hoʻohālikelike ʻia me nā kaohi olakino. ʻaʻa a me ka hana ʻino o ka ate. Hiki ke ʻimi ʻia nā pae lipid koko ma ke ʻano he kumu prognostic i nā mea maʻi COVID-19.
ʻO nā peptides natriuretic atrial a me ka lolo (ANP a me BNP) ke kahe nei i nā hormones o ke kumu cardiac e pāʻani i nā kuleana koʻikoʻi i ka hoʻoponopono ʻana i ke koko a me ka homeostasis wai a me ka hoʻomaikaʻi ʻana i ka hoʻoponopono ʻana o ka naʻau ma o nā hopena vasodilatory a me nā diuretic. peptide receptor-A (GC-A/NPR-A). ʻO ka hoʻopau ʻana i ka ʻōnaehana Npr1 gene (encoding GC-A/NPRA) ka hopena i ka nui o ka nui, hypertension, a me ka puʻuwai congestive. .ʻO ka pahuhopu o kēia noiʻi ʻana ʻo ia ka noiʻi ʻana inā he kuleana koʻikoʻi ka Npr1 i ka hoʻoponopono ʻana i ka homeostasis glucose i nā ʻiole Npr1 gene-disrupted.
ʻO nā kāne kāne a me nā wahine makua (16-18 pule) Npr1 knockout haplotype (Npr1+/-, 1-kope), wild-type (Npr1+/+, 2-kope) a me ka hoʻopili ʻana i nā gene (Npr1+ +/++, 4 -kopi) Mice ua hoʻokēʻai ʻia no nā hola 16 a ua loaʻa iā lākou ka wai. Ua hoʻoholo ʻia nā pae e ka huelo koko ma 0, 15, 30, 60, 90, a me 120 mau minuke me ka hoʻohana ʻana i ka AlphaTRAK Blood Glucose Monitoring System (Zoetis Inc, Kalamazoo, MI). tail-cuff ala (Visitech 2000).
Ua hōʻike ʻia nā hopena ua hoʻonui ʻia ke kiʻekiʻe o ka glucose koko i nā ʻiole kope 2 (OGTT: 101 ± 4 mg/dL) i ka palena kiʻekiʻe ma 15 mau minuke ma hope o ka hoʻohana ʻana i ka glucose (2 g/kg kino kaumaha) a ua hoʻemi i nā pae basal kokoke i 120 mau minuke i nā kāne. .a me nā wahine 98 ± 3 mg/dL, IPGT: nā kāne 100 ± 3 mg/dL, nā wahine 97 ± 4 mg/dL), akā i nā ʻiole kope 1, ua hoʻokiʻekiʻe ʻia nā pae glucose koko ma hope o 120 mau minuke (OGTT: kāne 244 ± 6 mg/dL, wahine 220 ± 4 mg/dL, IPGT: kāne 250 ± 5 mg/dL, wahine 225 ± 6 mg/dL) i hoʻohālikelike ʻia me nā ʻiole 2 kope. ʻO nā ʻiole 4 kope hoʻi ua emi loa ka pae glucose koko ma 120 mau minuke (OGTT: 78 ± 3 mg/dL no nā kāne, 73 ± 2 mg/dL no nā wahine, IPGT: 76 ± 4 mg/dL no nā kāne a me 70 ± 3 mg/dL no nā wahine).dL) i hoʻohālikelikeʻia me nāʻiole kope 2. Uaʻoi aku ka kiʻekiʻe o ka SBP ma nāʻiole kope 1 (134 ± 3 mmHg i nā kāne a me 125 ± 3 mmHg i nā wāhine) ma mua o nāʻiole 2-kopi (101 ± 2 mmHg i nā kāne a me 92 ± 2 mmHg i loko o nā wahine) .Pēia hoʻi, ua loaʻa i nā mice 4-copy i ka SBP nui loa ma mua o 2-copy mice (85 ± 3 mmHg i nā kāne a me 78 ± 2 mmHg i nā wahine). me ka IPGTT.
Hōʻike nā ʻike i kēia manawa ua pale nui ʻo Npr1 i ka piʻi nui ʻana o nā pae glucose koko ma hope o ka hoʻokūkū glucose a me ka hoʻomaikaʻi ʻana i ka glucose intolerance i nā ʻiole wild-type a me nā gene-replicated, e hōʻike ana he hana koʻikoʻi ʻo Npr1 i ka hoʻoponopono ʻana i nā pae glucose a me ka nalowale o ka Npr1 Action e hoʻopilikia maikaʻi ʻia. ʻO ka hana maʻi a me ka puʻuwai i nā ʻiole mutant. Ua kākoʻo ʻia kēia hana e kahi haʻawina NIH (HL062147).
Central Arkansas Veterans Healthcare System John L. McClellan Memorial Veterans Hospital, Little Rock, Arkansas
ʻO ka poʻe maʻi me ka maʻi maʻi maʻi maʻi (CKD) a me ka non-ST-segment elevation myocardial infarction (NSTEMI) e hōʻike ana i kahi pilikia koʻikoʻi. nā lapa'au i ka laulā like (2) Ua ho'ololi 'ia nā hopena e nā pae o ka hana renal?(3) Ua like ka nui o ka make me ka lā'au lapa'au wale nō ma nā ha'awina ho'okolo a me ka nānā 'ana?
Ua koho ʻia nā haʻawina ma muli o kēia mau pae hoʻohālikelike: (1) nā hōʻike i hoʻopaʻa ʻia a nānā ʻia paha o nā maʻi me NSTEMI a me CKD (2) helu o nā maʻi a me ka make i loaʻa no ka mālama invasive a conservative i kēlā me kēia pae o ka hana renal, me ka helu ʻana o ka glomerular filtration rate (eGFR). ) 30-60 a me <30. Ua hoʻopau ʻia kahi meta-analysis me nā hoʻohālikelike subgroup ma o ka helu ʻana i nā lakene kūʻokoʻa no nā make mai ka invasive versus conservative treatments.
(1) ʻElima mau haʻawina i hoʻopaʻa ʻia a me ʻehā mau noiʻi nānā ʻana i hoʻokō i nā pae koho, me ka huina o 362,486 mau maʻi e loaʻa ana i ka mālama invasive a conservative paha ma waena o 1994 a me 2020
(2) Ma nā haʻawina randomized, ʻo ka lakene o ka make ma muli o ka hoʻomaʻamaʻa invasive i nā poʻe maʻi me eGFR 30-60 he 0.739, ʻo ka manawa hilinaʻi (CI) he 0.382-1.431, p = 0.370. Ma kahi noiʻi nānā ʻana o eGFR 30-60, ʻO ka lākiō kūpilikiʻi no ka lāʻau invasive no ka make he 0.144, CI 0.012-0.892, p=0.037.
(3) Ma nā haʻawina randomized, ʻo ka ratio o ka make ma muli o ka mālama invasive i nā poʻe maʻi me eGFR <30 he 0.790, CI 0.135-4.63, p = 0.794. Ma nā haʻawina nānā, ua loaʻa i nā maʻi me ka eGFR <30 ka ratio o 0.384 no ka make, CI 0.281–0.552, p<.05.
(4) ʻO ka nui o ka hopena o ka make i nā maʻi me ka eGFR 30-60 i mālama ʻia me ka mālama conservative wale nō ʻo 0.128 (CI -0.001-0.227) i ka hui aʻo randomized a me 0.44 (CI 0.227-0.6525) i ka hui nānā ʻana, p< 0.01 .I ka randomized study ʻO ka pilikia o ka make ʻana o Median he 0.345 (CI -0.103-0.794) i nā maʻi me eGFR <30 e loaʻa ana i ka mālama conservative wale nō a me 0.463 (CI 0.00-0.926) i nā haʻawina nānā, p = 0.579.
(1) ʻOiai ka hopena maikaʻi o ka hoʻomaʻamaʻa invasive i nā haʻawina randomized a me nā haʻawina interventional, ʻoi aku ka nui o ka ratio o ka make ma nā haʻawina nānā.
(2) Ua hōʻike ʻia nā haʻawina nānā ʻana he haʻahaʻa haʻahaʻa haʻahaʻa ka lākiō o ka maʻi invasive no ka make ma nā maʻi me eGFR 30-60 a me eGFR <30.
(3) ʻO ka poʻe maʻi i loko o ka hui nānā i ʻoi aku ka nui o ka make me ka mālama conservative wale nō.
(4) Pono ka noiʻi hou aʻe no ka hoʻomohala ʻana i kahi kumu hoʻohālike no ke koho ʻana i nā maʻi e pōmaikaʻi nui mai ka mālama invasive a conservative paha.
(5) ʻO nā palena o kēia haʻawina e pili ana i nā ʻokoʻa o ka heluna o nā maʻi i loko o nā hui aʻo, nele i ka hemodynamic a me ka ʻikepili angiographic e like me ka eGFR, a me ka hiki ke komo i kekahi mau haʻawina i nā maʻi me ka angina pectoris paʻa ʻē aʻe ma mua o NSTEMI.
ʻOiai ka holomua o ka ʻenehana i ka cardiology, ʻo ka haʻalulu cardiogenic e like me ka hoʻopiʻi ʻana o ka myocardial infarction acute e noho mau i kahi pilikia olakino. me acute coronary syndrome (ACS). ʻO kā mākou pahuhopu e hoʻoholo i ke ʻano o ka mālama ʻana i ka haʻalulu cardiogenic i ke kula kiʻekiʻe i ka ACS e koi ana i ke kākoʻo ʻana i ke kaʻa uila i loko o kā mākou keʻena a e hoʻohālikelike i nā ʻano lapaʻau ma waena o nā mea ola a me nā mea ola ʻole.
ʻO kahi haʻawina retrospective o nā mea maʻi o 18-89 mau makahiki e koi ana i ke kākoʻo ʻana o ka mechanical circulatory i ke kahua ACS ma ke Kulanui o Texas Lubbock Medical Center mai ʻAukake 2018 a ʻAukake 2019. ua hoʻohana ʻia ka hōʻike hōʻuluʻulu no nā ʻano hoʻololi ʻano a me ka hoʻomau.
He 39 ka nui o na ma'i i komo, 90% he kane, he 62 makahiki ka makahiki, 62% ka ma'i ma'i ma'i, a he 29.01±5.84 kg/m2 ka mean body mass index. mea kākoʻo, ukali ʻia e Impella (92% vs 8%). ʻO 18% ka nui o ka make ʻana. mmol/l vs. .
ʻO ka piʻi ʻana o ka puʻuwai kiʻekiʻe a me nā pae lactate i ka wā o ka hoʻokomo ʻana i ke kākoʻo mechanical pili i ka make i nā maʻi me ka cardiogenic shock secondary to acute coronary syndrome.Hoʻomaka i ke kākoʻo mechanical ma mua o ka pili ʻana o PCI me ke ola. ʻO nā haʻawina nui a ʻoi aku ka ikaika e pono ai e wehewehe i kēia mau hui.
ʻO ka mālama ʻana i ka hidradenitis suppurativa (HS) hiki ke paʻakikī. I nā manawa he nui, ua hoʻomaikaʻi ʻia nā hōʻailona o nā maʻi ma hope o ka hana conservative mua. .Ke wehewehe nei mākou i ka mea maʻi i kūpaʻa ʻole i ka ʻoki ʻana i loaʻa i ka lāʻau radiation electron beam radiation.
Ua hōʻike ʻia kahi kanaka 44 makahiki me ka diffuse thickening o ka ʻāʻī, gluteal cleft, perineum, a me ka ʻūhā bilateral HS. ʻO ka mea maʻi i refractory i ka debridement surgical a me ka mālama ʻana me nā antibiotics a me nā corticosteroids. ka huina nui o 30 Gy i 10 puunaue puunaue a malama i ka pane hapa no 2 pule ma hope o ka hoʻomaka 'ana o ka lapaʻau. Objective kino kino i loko o 1 mahina o ka lapaʻau hōʻike i ka 25% ho'ēmi i loko o ka huina wahi o ka inflammatory a me ka hoailona flattening o ka hoalaia mai. I kēlā manawa, ua hōʻike nā mea maʻi i nā hoʻohaʻahaʻa kumuhana i ka ʻeha a me ka wai.
Loaʻa i ka lāʻau lapaʻau nā pōmaikaʻi anecdotal no nā ʻano maʻi maikaʻi ʻole a ua aʻo ʻia ma nā haʻahaʻa haʻahaʻa (i kekahi manawa hoʻokahi mau dosis) ma ka hoʻokele ʻana o HS. hoʻēmi i nā hopena ʻaoʻao.
Ka wahi lapaʻau o ka mea maʻi e hōʻike ana i ka hidradenitis suppurativa i loko o ka ʻāʻī, ka ʻāʻī gluteal, perineum a me nā ʻūhā bilateral ma mua o ka mālama ʻana.
He mea maikaʻi ka lāʻau lapaʻau electron beam radiation i ka mālama ʻana i nā maʻi maikaʻi a paʻa i ka ʻōlelo hoʻohiki no ka HS refractory.
Ma ka heluna nui o ka US, 1 i loko o 5,000 poʻe loaʻa ka myopathy mitochondrial. Hiki ke hoʻokaʻawale ʻia nā hōʻike clinical i ʻekolu mau ʻāpana: ophthalmoplegia o waho holomua holomua, skeletal-CNS syndrome a i ʻole myopathy maʻalahi. hypertrophic cardiomyopathy, dilated cardiomyopathy, a conduction abnormalities.We hōʻike i ka hihia o ka bilateral haʻahaʻa haʻahaʻa nawaliwali, eha, a pehu me ka muscle biopsy diagnostic of mitochondrial myopathy.Case wehewehe: He 21-makahiki-makahiki-kaki-kiekie haumāna haumāna puka i lawe 'ia i ko makou haukapila. ma hope o 3 mau pule o ka nāwaliwali o ka wāwae, ʻeha, a me ka pehu ma hope o ka hōʻea ʻana i ʻAmelika Hui Pū ʻIa mai India. Ua hōʻike ʻia ka nānā ʻana i ka tachycardia, 2+ mau wahi o ka pitting edema ma nā kuli ʻelua, 4/5 MRC-grade nāwaliwali, ʻoluʻolu ʻoluʻolu ma nā pūʻulu muscle proximal a me distal. ʻO nā ʻaoʻao o luna a me lalo, ʻaʻohe hohonu o ka tendon reflexes, hāʻule wāwae, a me ka ptosis bilateral a me ka neʻe ʻana o ka extraocular. ng / L, hoʻonui ʻia ka myoglobin e 195 ng / mL, a hoʻonui ʻia ka lactate e 7.7 mmol / L, ua hoʻemi ʻia ka bicarbonate serum e 12 mmol/L. ʻAʻole hiki ke hilinaʻi ʻia nā hopena o ka lumbar puncture i manaʻo ʻia ʻo Guillain-Barre syndrome ma muli o ka traumatic taps. ʻO ka hoʻokaʻawale ʻana me ka pūʻolo pūʻolo hema hema. ʻO ka X-ray a me ka CT angiography o ka umauma / ʻōpū / pelvis i hōʻike i ka hoʻonui ʻana o ka naʻau a me ka nui o ka nui. ʻO kona ʻaoʻao moe ECHO i hōʻike i ka hypokinesia systemic hema hema, 40-44% haʻahaʻa ejection haʻahaʻa, a me ka haʻahaʻa pulmonary hypertension. Ua hoʻokomo ʻia ka mea maʻi i ka ʻāpana mālama olakino ma muli o ka hāʻule ʻana o ka pressure inspiratory kiʻekiʻe. Ua hōʻoia ʻo Ophthalmology i ka ophthalmoplegia, me ka ʻole o ka maʻi lolo cranial, myasthenia gravis, a me retinitis pigmentosa.Gq1b antibody negative.Extensive autoimmune and infectious workup is non-contributing. Muscle biopsy o ka mea maʻi rectus femoris muscle ua hoʻopuehu i ka uliuli a me ka cytochrome-c oxidase-negative fibers me ka hoʻonui perimuscular a me ka endomysial connective kino, e like me ka hana a me ka maʻiʻo mitochondrial myopathy.Endomyocardial biopsy hōʻike ikaika lymphocytic myocarditis.O ka mea maʻi ua holomua me ka furosemide, metoprolol, a me methylprednisolone.
Pono e noʻonoʻo ʻia ka myopathy i ka ʻike ʻokoʻa o nā maʻi me ka Guillain-Barre Syndrome. ka hoʻokokoke ʻana e ʻike i nā pathologies loaʻa me ke komo ʻana o nā multisystem ākea ākea.
ʻO ke kumu o kēia noiʻi ʻana ʻo ka ʻimi ʻana i ka hiki ke hoʻopaʻa ʻia ʻo Gaisbock i nā poʻe maʻi me ka polycythemia maʻi a me ke kiʻekiʻe.
Ua hoʻokomo ʻia kekahi kanaka Caucasian obese 40 makahiki i ka haukapila me ka pehu mau wāwae a hoʻonui i ka koi o ka oxygen ma hope o ʻelua pule o ka hale maʻi me COVID-19 pneumonia. he ʻumi makahiki ma kekahi mau kipa ʻana. ʻO ka moʻolelo olakino hou loa he hōʻailona o ka thrombosis vein hohonu (DVT) ma ka wāwae hoʻokahi ʻelua a me ka hapa mahina i hala, a me ka mālama ʻana me Xarelto.
Ua hōʻike ka mea maʻi i kahi moʻolelo 12 makahiki o ka testosterone haʻahaʻa. Akā naʻe, ʻaʻole ʻo ia i hoʻohana i nā mea hoʻohui testosterone no nā mahina ʻeiwa i hala. Ua hōʻike ʻo ia i ka luhi o ke ao, ala pinepine i ka pō, a me ka snoring pinepine. Ua puhi ka mea maʻi i ka hapalua o ke kini o ka nau paka i ka lā no 13 mau makahiki, hoʻokahi ʻeke i ka lā, no 10 mau makahiki, a haʻalele i ka puhi paka 12 mau makahiki i hala.
Ka manawa hoʻouna: Iune-29-2022